MA44054A - Plateforme d'anticorps bispécifique - Google Patents

Plateforme d'anticorps bispécifique

Info

Publication number
MA44054A
MA44054A MA044054A MA44054A MA44054A MA 44054 A MA44054 A MA 44054A MA 044054 A MA044054 A MA 044054A MA 44054 A MA44054 A MA 44054A MA 44054 A MA44054 A MA 44054A
Authority
MA
Morocco
Prior art keywords
bispecific antibody
antibody platform
platform
bispecific
antibody
Prior art date
Application number
MA044054A
Other languages
English (en)
French (fr)
Inventor
Martin Preyer
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA44054A publication Critical patent/MA44054A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA044054A 2015-12-18 2016-12-15 Plateforme d'anticorps bispécifique MA44054A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562269664P 2015-12-18 2015-12-18

Publications (1)

Publication Number Publication Date
MA44054A true MA44054A (fr) 2018-10-24

Family

ID=57681809

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044054A MA44054A (fr) 2015-12-18 2016-12-15 Plateforme d'anticorps bispécifique

Country Status (9)

Country Link
US (1) US11447575B2 (enExample)
EP (1) EP3389710A1 (enExample)
JP (2) JP7138046B2 (enExample)
KR (1) KR20180100136A (enExample)
CN (1) CN108601830B (enExample)
AU (1) AU2016370821A1 (enExample)
CA (1) CA3008840A1 (enExample)
MA (1) MA44054A (enExample)
WO (1) WO2017106462A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034768A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
EP4088783A1 (en) 2017-08-01 2022-11-16 Ab Studio Inc. Bispecific antibodies and uses thereof
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
AU2019371814A1 (en) 2018-10-29 2021-06-17 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
EP3917579A4 (en) 2019-01-28 2023-03-29 AB Therapeutics, Inc. SPECIFIC ANTIBODIES AND USES THEREOF
WO2020192648A1 (en) * 2019-03-25 2020-10-01 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
WO2021030680A1 (en) * 2019-08-15 2021-02-18 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules for cell targeting and uses thereof
CA3149350A1 (en) * 2019-08-23 2021-03-04 Igm Biosciences, Inc. Igm glycovariants
WO2021058804A1 (en) * 2019-09-25 2021-04-01 Universität Stuttgart Binding modules comprising modified ehd2 domains
WO2021139758A1 (zh) * 2020-01-09 2021-07-15 江苏恒瑞医药股份有限公司 新型多肽复合物
CN113307879A (zh) * 2020-02-27 2021-08-27 启愈生物技术(上海)有限公司 一种taa/ctla-4/il15三功能融合蛋白及其应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2022096704A1 (en) * 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
MX2023013307A (es) * 2021-05-14 2023-12-04 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno.
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
JP2025532897A (ja) * 2022-09-28 2025-10-03 ドレン バイオ， インコーポレイテッド 多重特異性抗体及びその使用方法
WO2025042806A2 (en) 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN103403025B (zh) * 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
US9738707B2 (en) * 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
JP2015520168A (ja) * 2012-05-24 2015-07-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 多重特異性抗体
EP3057990B1 (en) * 2013-10-18 2019-09-04 Regeneron Pharmaceuticals, Inc. Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
JP6904902B2 (ja) * 2014-12-05 2021-07-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ドメイン交換抗体
US20180194861A1 (en) * 2015-07-10 2018-07-12 Abbvie Inc. IgM- or IgE-Modified Binding Proteins and Uses Thereof
CA3034768A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
CN119896730A (zh) * 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物

Also Published As

Publication number Publication date
AU2016370821A1 (en) 2018-07-12
JP7138046B2 (ja) 2022-09-15
JP2019502694A (ja) 2019-01-31
EP3389710A1 (en) 2018-10-24
CN108601830A (zh) 2018-09-28
JP2021121642A (ja) 2021-08-26
WO2017106462A1 (en) 2017-06-22
KR20180100136A (ko) 2018-09-07
US20190048098A1 (en) 2019-02-14
CN108601830B (zh) 2023-02-03
CA3008840A1 (en) 2017-06-22
US11447575B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
MA44054A (fr) Plateforme d'anticorps bispécifique
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
FR25C1022I1 (fr) Anticorps anti-pd-1
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
EP3423089A4 (en) ANTI-Tigit ANTIBODY
MA47268A (fr) Anticorps anti-gpc3
EP3334757A4 (en) ANTI-Tigit ANTIBODY
EP3334824A4 (en) PD-1 ANTIBODY
EP3297671A4 (en) ANTI-ROR1 ANTIBODY
EP3387442A4 (en) HUMANIZED ANTI-CD73 ANTIBODIES
EP3359573A4 (en) MARKING OF ANTIBODIES
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3334763A4 (en) NOVEL ANTI-PD-1 ANTIBODIES
EP3503920A4 (en) ANTI-CTLA4 ANTIBODIES
MA50352A (fr) Anticorps multispécifiques
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3383915A4 (en) PD-1 ANTIBODY
EP3307321A4 (en) MULTISPECIFIC ANTIBODY PLATFORM AND ASSOCIATED METHODS
EP3496753A4 (en) PD-1 ANTIBODY FORMULATION
EP3526247A4 (en) Anti-il1-rap antibodies
EP3399992A4 (en) SELF-NETWORKING ANTIBODIES